Advanced Hepatocellular Carcinoma

Oncology·MeSH: Carcinoma, Hepatocellular

Prevalence

12.0 / 100K

Incidence

8.6 / 100K/yr

14 drugs in development·8 companies·8 clinical trials

Drug Pipeline by Phase

Phase 3(6)

Drug	Company
anti-thymocyte globulin	Filana Therapeutics Inc. (FLNA)
fludarabine	Filana Therapeutics Inc. (FLNA)
horse anti-thymocyte globulin	Filana Therapeutics Inc. (FLNA)
rabbit anti-thymocyte globulin	Filana Therapeutics Inc. (FLNA)
tremelimumab	CG Oncology, Inc. (CGON)
Tremelimumab	ASTRAZENECA PLC (AZN)

Phase 2(6)

Drug	Company
ABT-869	AbbVie Inc. (ABBV)
ALN-BCAT	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Anti-GPC3-CAR Autologous T Lymphocytes	Filana Therapeutics Inc. (FLNA)
Cabozantinib	UNITED THERAPEUTICS Corp (UTHR)
Lenvatinib	UNITED THERAPEUTICS Corp (UTHR)
Lenvatinib Mesylate	UNITED THERAPEUTICS Corp (UTHR)

Phase 1(2)

Drug	Company
Sapanisertib	Royalty Pharma plc (RPRX)
Sapanisertib	Merus N.V. (MRUS)

BioSniper tracks 14 drugs in development for Advanced Hepatocellular Carcinoma across 8 companies.

There are 8 clinical trials targeting Advanced Hepatocellular Carcinoma tracked by BioSniper.

The estimated prevalence of Advanced Hepatocellular Carcinoma is approximately 12.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.